| Identification | Back Directory | [Name]
ITI-722 | [CAS]
313368-91-1 | [Synonyms]
ITI-722
Lumateperone
ITI-722 lumateperone
Lumateperone ITI-722
313368-91-1Lumateperone(ITI-007)
1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3‘,4‘:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-one
1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one
1-(4-Fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone
1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-
presynaptic D2 receptor,dopamine D1 receptor,Serotonin Receptor,postsynaptic D2 receptor,Dopamine Receptor,5-HT2A,schizophrenia,ITI 007,Lumateperone,inhibit,Inhibitor,5-HT Receptor,5-hydroxytryptamine Receptor | [Molecular Formula]
C24H28FN3O | [MDL Number]
MFCD28502161 | [MOL File]
313368-91-1.mol | [Molecular Weight]
393.497 |
| Chemical Properties | Back Directory | [Boiling point ]
556.4±50.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [form ]
Oil | [pka]
9.10±0.20(Predicted) | [color ]
Colorless to light yellow | [InChIKey]
HOIIHACBCFLJET-SFTDATJTSA-N | [SMILES]
C(C1=CC=C(F)C=C1)(=O)CCCN1C[C@@]2([H])C3=CC=CC4=C3N([C@@]2([H])CC1)CCN4C |
| Hazard Information | Back Directory | [Description]
Lumateperone is a novel antipsychotic agent with a unique mechanism of
action with high 5-hydroxytryptamine 2A(5-HT2A) blocking activity. A
Phase 2 study in treatment of insomnia revealed strong evidence of
efficacy, with no impairment of next-day cognition.
| [Uses]
Lumateperone was a drug developed for the treatment of schizophrenia. May have applications in bipolar depression. | [Synthesis]
Synthesis of Lumateperone
 | [in vivo]
Lumateperone (i.p., 1-10 mg/kg) promotes NMDA and AMPA-induced currents in a dopamine D1 receptor-dependent manner and increases the release of dopamine and glutamate in rat mPFC slices[2].
| Animal Model: | Adult male Sprague-Dawley rats[2] | | Dosage: | 1-10 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Inhibited avoidance response at concentrations of 1, 3 and 10 mg/kg after 20 minutes.
Promoted NMDA and AMPA-sensitive currents, also significantly increased dopamine and glutamate release at 10 mg/kg in mPFC cone cells of rat.
|
| [IC 50]
D1 Receptor; D2 Receptor | [storage]
Store at 0-8℃ | [References]
[1] Patent: US2004/220178, 2004, A1 |
|
|